02702nas a2200229   4500008004100000020001400041024001700055245006700072210006500139260029900204300001400503490000700517520176300524100002102287700001902308700002102327700002002348700001502368700002102383700002302404856004502427       2015                        eng d  a0041-1132  awdn, 041736000aTransfusion-related adverse events in the Platelet Dose study.0 aTransfusionrelated adverse events in the Platelet Dose study  a(C) 2015 John Wiley & Sons, Ltdb(1) Brigham and Women's Hospital, Boston, Massachusetts,(2) Center for Statistical Analysis and Research, New England Research Institutes, Watertown, Massachusetts,(3) Department of Pathology, Division of Transfusion Medicine, University of Pittsburgh, Pic2015  a144 - 1530 v553 aBACKGROUND: How platelet (PLT) product characteristics such as dose, source (whole blood derived [WBD] vs. apheresis), storage duration, and ABO matching status affect the risks of transfusion-related adverse events (TRAEs) is unclear. Similarly, more information is needed to define how recipient characteristics affect the frequency of TRAEs after PLT transfusion., STUDY DESIGN AND METHODS: In the multicenter Platelet Dose ("PLADO") study, pediatric and adult hematology-oncology patients with hypoproliferative thrombocytopenia were randomized to receive low-dose (LD), medium-dose (MD), or high-dose (HD) PLT prophylaxis for a pretransfusion PLT count of not more than 10 x 109/L. All PLT units (apheresis or WBD) were leukoreduced. Post hoc analyses of PLADO data were performed using multipredictor models., RESULTS: A total of 5034 PLT transfusions to 1102 patients were analyzed. A TRAE occurred with 501 PLT transfusions (10.0%). The most common TRAEs were fever (6.6% of transfusions), allergic or hypersensitivity reactions (1.9%), and sinus tachycardia (1.8%). Patients assigned HD PLTs were more likely than LD or MD patients to experience any TRAE (odds ratio for HD vs. MD, 1.50; 95% confidence interval, 1.10-2.05; three-group comparison p = 0.02). PLT source and ABO matching status were not significantly related to overall TRAE risk. Compared to a patient's first PLT transfusion, subsequent PLT transfusions were less likely to have a TRAE reported, primarily due to a lower risk of allergic or hypersensitivity reactions., CONCLUSION: The most important PLT unit characteristic associated with TRAEs was PLT dose per transfusion. HD PLTs may increase the risk of TRAEs, and LD PLTs may reduce the risk., (C) 2015 John Wiley & Sons, Ltd1 aKaufman, Richard1 aAssmann, Susan1 aTriulzi, Darrell1 aStrauss, Ronald1 aNess, Paul1 aGranger, Suzanne1 aSlichter, Sherrill  uhttp://613633.bywedr.asia/reference/4213